Xpovio mulligan in endometrial cancer comes up short as Karyopharm presses on in myelofibrosis

Reporting a new miss in one indication, Karyopharm Therapeutics is plowing ahead with plans to advance its XPO1 inhibitor Xpovio in another, despite investors blanching at that dataset back in Marc | Reporting a new miss in one indication, Karyopharm is plowing ahead with plans to advance its XPO1 inhibitor Xpovio in another, despite investors blanching at that dataset back in March.